Ceramide NanoLiposome in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

March 15, 2017

Primary Completion Date

August 3, 2023

Study Completion Date

November 1, 2023

Conditions
CancerCarcinomaSolid TumorsTumor
Interventions
DRUG

Ceramide NanoLiposome

Intravenous administration of Ceramide NanoLiposome

Trial Locations (3)

21201

University of Maryland, Greenebaum Cancer Center, Baltimore

22908

University of Virginia Cancer Center, Charlottesville

29425

Medical University of South Carolina, Hollings Cancer Center, Charleston

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

Keystone Nano, Inc

INDUSTRY